Working… Menu

Feasibility of a Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy (LaHoST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01825915
Recruitment Status : Unknown
Verified April 2013 by A.I. Hasib Ahmed, Medway NHS Foundation Trust.
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2013
Last Update Posted : April 8, 2013
Johnson & Johnson
Information provided by (Responsible Party):
A.I. Hasib Ahmed, Medway NHS Foundation Trust

Brief Summary:

Observational studies suggest faster recovery and quicker return to normal activities following laparoscopic supracervical hysterectomy (LSH which involves removal of the body of the womb but conservation of the neck of the womb or cervix) compared with laparoscopic hysterectomy (LH in which both the body and neck of the womb are removed) in women with benign uterine disease. Data from the only randomised controlled trial (RCT) on the topic does not support this observation.

The investigators set out to investigate the feasibility of a double blind RCT comparing post-operative recovery following LH with that following LSH.

The investigators set out to recruit 50 participants from a single gynaecological surgeon's caseload. Web based randomisation was carried out at the time of study laparoscopy. Surgery was performed using a standardised technique.

Participants and the data handler were blinded to treatment allocation (double blind study where neither the patient nor the surgeon have knowledge of treatment group allocation at the time of questionnaire analysis).

Primary outcome is feasibility of recruitment to the study. The null hypothesis for this study is that 'a double blind, randomised controlled comparison of recovery following laparoscopic hysterectomy with recovery following laparoscopic sub-total hysterectomy' is not feasible.

Secondary outcomes included validated post-operative recovery and mood questionnaires at baseline, prior to discharge and at weekly intervals for 12 weeks. Validated questionnaires regarding pelvic floor function and sexual function will be assessed at baseline, 6 weeks and 6 months.

The findings of the feasibility study will inform the power calculation for a planned definitive study ( the magnitude of the differences found between the 2 arms of the feasibility study will allow calculation of the total number of participants required in a definitive study to allow demonstration of statistically significant differences in outcomes).

Condition or disease Intervention/treatment Phase
Benign Disease of the Uterus Procedure: Laparoscopic Hysterectomy Procedure: Laparoscopic Supracervical Hysterectomy Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Feasibility of a Randomised Controlled Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy
Study Start Date : September 2010
Actual Primary Completion Date : November 2012
Estimated Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hysterectomy

Arm Intervention/treatment
Active Comparator: Laparoscopic Hysterectomy
Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
Procedure: Laparoscopic Hysterectomy
Active Comparator: Laparoscopic Supracervical Hysterectomy
Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
Procedure: Laparoscopic Supracervical Hysterectomy

Primary Outcome Measures :
  1. Study Feasibility [ Time Frame: 30 Months ]
    Rate of recruitment. Rate of refusal. Completion of data at enrolment, at 12 weeks, at 6 months, at 12 months.

Secondary Outcome Measures :
  1. Post-operative recovery [ Time Frame: 30 months ]
    Quality of recovery measured with validated questionnaires QoR 40 Myles 2006

Other Outcome Measures:
  1. Depression score [ Time Frame: 30 months ]
    Depression score calculated with validated questionnaire CES-D Stanford 1996.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 54 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hysterectomy indicated for benign indications
  • Premenopausal

Exclusion Criteria:

  • Post menopausal women
  • Suspected malignancy
  • Abnormal cervical smears or a history of treatment of a high grade cervical intraepithelial neoplasia within 3 years of recruitment.
  • Raised BMI (Body Mass Index) > 35Kg/M2
  • Uterovaginal prolapse > Stage 1 (Bump et al 1996).
  • Previous gynaecological malignancy
  • Previous extensive pelvic surgery
  • Psychological/psychiatric disease
  • Anti-depressant/anti-psychotic therapy
  • Unable to read and write English

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01825915

Layout table for location information
United Kingdom
Medway NHS Foundation Trust
Gillingham, Kent, United Kingdom, ME7 5NY
Sponsors and Collaborators
Medway NHS Foundation Trust
Johnson & Johnson

Layout table for additonal information
Responsible Party: A.I. Hasib Ahmed, Clinical Director of Women's Health, Medway NHS Foundation Trust Identifier: NCT01825915    
Other Study ID Numbers: LaHoST protocol (v2)
First Posted: April 8, 2013    Key Record Dates
Last Update Posted: April 8, 2013
Last Verified: April 2013
Keywords provided by A.I. Hasib Ahmed, Medway NHS Foundation Trust: